- Home
- AVTX vs DBVT Comparison
AVTX vs DBVT Comparison
Compare AVTX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | DBVT |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | France |
| Employees | 33 | 90 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.6M | 850.9M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVTX | DBVT |
|---|---|---|
| Price | $16.51 | $12.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $40.57 | $32.04 |
| AVG Volume (30 Days) | ★ 856.9K | 270.1K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2312.27 | 35.77 |
| 52 Week Low | $10.70 | $8.86 |
| 52 Week High | $24.27 | $26.19 |
Technical Indicators
Market Signals| Indicator | AVTX | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 37.80 |
| Support Level | $15.29 | $11.70 |
| Resistance Level | $16.80 | $14.90 |
| Average True Range (ATR) | 1.00 | 0.50 |
| MACD | -0.20 | -0.07 |
| Stochastic Oscillator | 23.14 | 14.73 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.